Cultivating the microbiome to enhance cancer immunotherapy

IF 94.6 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2026-04-09 DOI:10.1038/s41571-026-01146-x

Erez N. Baruch, Nadim J. Ajami, Jennifer A. Wargo

引用次数: 0

Abstract

Three recently published studies demonstrate the feasibility of modulating gut microorganisms using faecal microbiota transplantation (FMT) in patients receiving immune-checkpoint inhibitors (ICIs) in the first-line setting, expanding the evidence that FMT can augment response to ICIs. Herein, we discuss several opportunities for refining these efforts in order to increase the rigour and clinical benefit from microbiota modulation trials in oncology.

查看原文本刊更多论文

培养微生物群增强癌症免疫治疗。

最近发表的三项研究表明，在一线接受免疫检查点抑制剂（ICIs）治疗的患者中，使用粪便微生物群移植（FMT）调节肠道微生物的可行性，进一步证明了FMT可以增强对ICIs的反应。在此，我们讨论了几个改进这些努力的机会，以提高肿瘤学微生物群调节试验的严谨性和临床效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.